Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.

Respiratory medicine - 1 Jan 2000

Schmid Ulrike, Weber Benjamin, Magnusson Mats O, Freiwald Matthias

Abstract excerpt

BACKGROUND: The tyrosine kinase inhibitor nintedanib reduces the rate of decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib is 150 mg twice daily (BID). METHODS: Data from Phase II and III trials in IPF,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Drug Monitoring

Share to Idiopathic Pulmonary Fibrosis

Share to Indoles

Share to Lung Diseases, Interstitial

Share to Vital Capacity

Source

Identifiers

PMID: 33798871
DOI: 10.1016/j.rmed.2021.106369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.PMID 33798871Read ↗

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study.Semantic proximity Read ↗

Progressive fibrotic interstitial lung disease.Semantic proximity Read ↗

Expression profiles of nintedanib-targeting molecules in progressive fibrotic interstitial lung diseases (non-IPF-PF) and IPFSemantic proximity Read ↗

Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.Semantic proximity Read ↗

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).Semantic proximity Read ↗

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.Semantic proximity Read ↗

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.Semantic proximity Read ↗

Inhibition of fibrosis with multi-agent therapy in pulmonary fibrosis: Results of a drug library screeningSemantic proximity Read ↗

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutationSemantic proximity Read ↗

Is earlier always better? Timing of antifibrotic therapy and overall survival in idiopathic pulmonary fibrosis: a multicenter retrospective studySemantic proximity Read ↗

Tumor growth inhibition modeling to support the starting dose for dacomitinib.Semantic proximity Read ↗

A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.